Ifinatamab deruxtecan
Based on 1 publication(s) in Google Scholar
Ifinatamab deruxtecan (DS-7300a) is a B7-H3-targeting Antibody-drug conjugate (ADC), which is composed of a humanized anti-B7-H3 monoclonal antibody, an enzymatically cleavable peptide-based linker, and Exatecan derivative (DXd) (HY-13631D). Ifinatamab deruxtecan is a DNA Topoisomerase I inhibitor. Ifinatamab deruxtecan induces Apoptosis. DS-7300a exerts potent antitumor activities against B7-H3-expressing tumors. against rhabdomyosarcoma, endometrial adenocarcinoma and lung adenocarcinoma. Ifinatamab deruxtecan does not exert direct immunomodulatory effects
For research use only. We do not sell to patients.
- Purity : 99.07%
- CAS No.: 2484870-92-8
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-141598
Datopotamab deruxtecan (solution)TROP2-Targeted ADC -
HY-132254
Sacituzumab govitecanTrop-2 ADC -
HY-138298
Trastuzumab deruxtecan (solution)HER2 ADC -
HY-138298A
Trastuzumab deruxtecanHER2 ADC -
HY-P99813
Patritumab deruxtecanHER3-Directed ADC -
HY-141601
Telisotuzumab vedotinAnti-c-MET ADC -
HY-P99367
IfinatamabAnti-Human B7-H3 Antibody -
HY-132254A
Sacituzumab govitecan (solution)Trop-2 ADC -
HY-P9921
Trastuzumab emtansineAntibody-drug Conjugate -
HY-P9921A
Trastuzumab emtansine (solution)Antibody-Drug Conjugate -
HY-132258A
Mirvetuximab soravtansine (solution)ADC -
HY-132253
Polatuzumab vedotinMicrotubule Inhibitor
Publications Citing Use of MedChemExpress (MCE) Ifinatamab deruxtecan
MoreAll Topoisomerase Isoforms
More
Biological Activity
Description
IC50 & Target
[2]|
Topoisomerase I |
In Vitro
Ifinatamab deruxtecan inhibits the growth of B7-H3-expressing cancer cells in vitro, but not of B7-H3-negative cancer cells[1].
Ifinatamab deruxtecan (6 days) potently and selectively inhibits the growth of B7-H3-expressing RH-41 and MFE-280 cancer cells in vitro, with no activity against B7-H3-negative CCRF-CEM cells[2].
Ifinatamab deruxtecan (10 μg/mL; 72 hours) induces DNA damage and apoptosis in B7-H3-expressing RH-41 cancer cells in vitro[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human rhabdomyosarcoma (RH-41) cells
-
Concentration:10 μg/mL
-
Incubation Time:72 h
-
Result:Induced phosphorylation of Chk1 (a DNA damage marker) in RH-41 cells. Induced cleavage of PARP (an apoptosis marker) in RH-41 cells.
Parmacokinetics
In Vivo
Ifinatamab deruxtecan (0.3-3 mg/kg; i.v.; days 0 and 14) exerts potent antitumor activity against endometrial adenocarcinoma xenografts in mice, achieving 67% TGI at 0.3 mg/kg and complete tumor growth inhibition (100% TGI) at 1 mg/kg and 3 mg/kg[2].
Ifinatamab deruxtecan (1-10 mg/kg; i.v.; days 0 and 14) exerts potent dose-dependent antitumor activity against lung adenocarcinoma xenografts in mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CAnN.Cg-Foxn1nu/CrlCrlj (lung adenocarcinoma xenograft model)[2]
-
Dosage:1 mg/kg; 3 mg/kg; 10 mg/kg
-
Administration:i.v.; days 0 and 14
-
Result:Achieved tumor growth inhibition (TGI) of 71% at 1 mg/kg compared to vehicle control group (P < 0.001).\nAchieved tumor growth inhibition (TGI) of 95% at 3 mg/kg compared to vehicle control group (P < 0.001).\nAchieved tumor growth inhibition (TGI) of 99% at 10 mg/kg compared to vehicle control group (P < 0.001).
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2484870-92-8
-
Appearance Liquid
-
Color Colorless to light yellow
-
SMILES
[Ifinatamab deruxtecan]
-
Synonyms
DS-7300a; MABX-9001a; I-DXd
-
Shipping
Shipping with dry ice.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[2]. Yamato M, et al. DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody-Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models. Mol Cancer Ther. 2022;21(4):635-646. [Content Brief]
[4]. Rudin CM, et al. Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial. J Clin Oncol. 2026;44(4):261-273. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Ifinatamab deruxtecan Related Classifications
HY-P3371 Related Classifications
Powered by Bioz
Keywords
- Ifinatamab deruxtecan
- 2484870-92-8
- DS-7300a
- MABX-9001a
- I-DXd
- Antibody-Drug Conjugates (ADCs)
- Topoisomerase
- Apoptosis
- CD276/B7-H3
- Antibody-Drug Conjugates
- ADC
- B7 homolog 3 protein
- cynomolgus monkeys
- metastatic castration-resistant prostate cancer
- patient-derived xenograft mouse models
- B7-H3-expressing solid tumors
- rats
- tumor xenograft
- apoptosis
- B7-H3 (CD276)
- cancer cells
- DNA topoisomerase I
- Inhibitor
- inhibitor
- inhibit